KRAS mutations are found in many types of tuman tumors and remain one of the most frequently activated oncogenes yet discovered.
Characterization of such mutations can help inform treatment options post-diagnosis because there are several FDA-approved options to treat KRAS-positive cancer, such as Sotorasib for KRAS G12C-mutated NSCLC. Additionally, KRAS mutations can be used as a selection marker for EGFR inhibitor treatment, as KRAS mutations are associated with a lack of response to EGFR inhibitors.
KRAS mutations can also indicate to clinicians what the potential prognosis might be. Recent studies have shown significantly different outcomes between patients with KRAS-mutation-positive cancer compared to those without KRAS mutations.
The majority of KRAS mutations occur within three codons. Therefore, a robust and targeted means of sequencing can improve detection rates and accuracy, informing better treatment options for clinicians. Ensuring that your protocol uses standard equipment, is optimized, and contains a streamlined workflow with adequate sequencing coverage is essential for success.
Download this protocol guide to learn:
The importance of using KRAS mutations to detect different types of cancer
How to use KRAS mutations to detect cancer
An optimized Sanger sequencing procedure for the detection of KRAS mutations
KRAS mutations and associated nucleotide changes
How to select a genetic analyzer and other materials to accurately detect KRAS mutations